Company news

Rein Therapeutics, Inc. news in 2026

Rein Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results

November 16, 2026

Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

November 2, 2026

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

September 4, 2026

Rein Therapeutics to Present at Upcoming September Investor Conferences

September 3, 2026

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

August 20, 2026

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

August 4, 2026

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

July 20, 2026

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

June 11, 2026

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

May 18, 2026

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

April 29, 2026

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

April 29, 2026

Amendment to Annual Report (Form 10-K/A)

April 27, 2026

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

March 2, 2026

Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

January 20, 2026

Decks in 2026